Donate Now Become a member

Cart (0)

Already a DIA Member? Sign in. Not a member? Join.

Not a Member?

Create Account and Join

Bethesda North Marriott Hotel and Conference Center

Oct 28, 2019 7:00 AM - Oct 30, 2019 12:30 PM

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

DIA/FDA Oligonucleotide-Based Therapeutics Conference

Back to Agenda

Session 2 Track A: Clinical Experience with Immune-Targeting Oligonucleotides and MicroRNAs

Session Chair(s)

Arthur M. Krieg, MD

CEO and CSO

Checkmate Pharmaceuticals, United States

Daniela Verthelyi, MD, PhD

Chief, Laboratory of Immunology, OBP, OPQ, CDER

FDA, United States

Therapeutic oligonucleotides offer a remarkable breadth of mechanisms and applications aside from inducing the cleavage of a target mRNA. This session explores a few of these including activating anti-tumor immunity with CpG DNA through TLR9 or with RNA and regulating the function of microRNAs.

Learning Objective : At the conclusion of this session, participants should be able to:
Describe the immune pathways that can detect foreign RNA and DNA
Recognize how immune activation by DNA and RNA can trigger anti-tumor immunity
Understand how microRNAs can be modulated to regulate cell functions

Speaker(s)

Overcoming Resistance to Checkpoint Inhibition with Intratumoral or Systemic Injection of a CpG-A TLR9 Agonist

Arthur M. Krieg, MD

Checkmate Pharmaceuticals, United States

CEO and CSO

Antitumoral T-Cell Immunity Triggered by Systemic RNA Lipoplex Vaccination in Cancer Patients

Mathias Vormehr, PhD

BioNTech RNA Pharmaceuticals GmbH, Germany

Head of Cancer Vaccines

Clinical Development of microRNA Inhibitors

Diana Escolar, MD

Miragen, United States

Senior Vice President Medical Science

Have an account?

DIA/FDA Oligonucleotide-Based Therapeutics Conference

Session 2 Track A: Clinical Experience with Immune-Targeting Oligonucleotides and MicroRNAs

Session Chair(s)

Arthur M. Krieg, MD

Daniela Verthelyi, MD, PhD

Learning Objective : At the conclusion of this session, participants should be able to:Describe the immune pathways that can detect foreign RNA and DNARecognize how immune activation by DNA and RNA can trigger anti-tumor immunityUnderstand how microRNAs can be modulated to regulate cell functions

Speaker(s)

Overcoming Resistance to Checkpoint Inhibition with Intratumoral or Systemic Injection of a CpG-A TLR9 Agonist

Antitumoral T-Cell Immunity Triggered by Systemic RNA Lipoplex Vaccination in Cancer Patients

Clinical Development of microRNA Inhibitors

Be informed and stay engaged.